Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psori...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

MedicalDoctorInvestor Oct. 27 at 10:46 PM

$CRVS what sort of stupid is going on here today?

1 · Reply

biotech_loser Oct. 27 at 10:02 PM

$CRVS MC 550, conservatively, after more data comes out $5B valuation is reasonable. That puts it at 70-80 per share. This might be the next VRNA kinda stock. It can easily be more than 70-80, but let’s not get too excited, let the data come and dictate the stock price.

0 · Reply

Jellysquid1 Oct. 27 at 8:35 PM

$CRVS New Article! Just Came Out! Game Changer For Lymphoma $10.00 Next Leg Up!

1 · Reply

dwsrph1 Oct. 27 at 6:54 PM

$CRVS $CRVS this stock is a no brainer!! No need to say anymore!! 😊

0 · Reply

dwsrph1 Oct. 27 at 5:26 PM

$CRVS not only should we break 8 We should be breaking 60 by now Time will tell.

1 · Reply

tradingjunk321 Oct. 27 at 4:43 PM

$CRVS Up, Volume picking up and all $8,9,10 & $11 different call series picking up 🤔

1 · Reply

Jellysquid1 Oct. 27 at 2:37 PM

$CRVS Heading Up!

1 · Reply

Jellysquid1 Oct. 26 at 2:54 PM

$CRVS IDIOT BELOW! Med Doctor 👇👇👇👇

2 · Reply

MedicalDoctorInvestor Oct. 25 at 8:09 PM

$CRVS if after market selling is any indicator, Monday morning could be bloody

1 · Reply

TheGunnerAB Oct. 25 at 11:48 AM

$CRVS Short Interest dropped 1.2M shares. That's 120K shares covered per day on average.

1 · Reply

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 25 days ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 12, 2025, 11:31 PM EDT - 2 months ago

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Aug 8, 2025, 3:20 PM EDT - 2 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 5 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 11:57 AM EDT - 6 months ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 8, 2025, 11:06 PM EDT - 6 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:02 PM EDT - 6 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 23, 2025, 4:08 PM EDT - 6 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 28, 2025, 9:30 AM EDT - 7 months ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:29 AM EDT - 7 months ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 25, 2025, 7:58 PM EDT - 7 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 7 months ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 8 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 4, 2025, 8:00 AM EST - 9 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 13, 2025, 7:30 AM EST - 10 months ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 10 months ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 11 months ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 11 months ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 11 months ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 11 months ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 11 months ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 11 months ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 1 year ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 1 year ago

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Aug 9, 2024, 10:22 PM EDT - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

$Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)$

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jun 20, 2024, 6:53 AM EDT - 1 year ago

Corvus Pharmaceuticals Is Ready To Take Flight

May 30, 2024, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

May 6, 2024, 7:53 PM EDT - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

May 2, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

MedicalDoctorInvestor Oct. 27 at 10:46 PM

$CRVS what sort of stupid is going on here today?

1 · Reply

biotech_loser Oct. 27 at 10:02 PM

0 · Reply

Jellysquid1 Oct. 27 at 8:35 PM

$CRVS New Article! Just Came Out! Game Changer For Lymphoma $10.00 Next Leg Up!

1 · Reply

dwsrph1 Oct. 27 at 6:54 PM

$CRVS $CRVS this stock is a no brainer!! No need to say anymore!! 😊

0 · Reply

dwsrph1 Oct. 27 at 5:26 PM

$CRVS not only should we break 8 We should be breaking 60 by now Time will tell.

1 · Reply

tradingjunk321 Oct. 27 at 4:43 PM

$CRVS Up, Volume picking up and all $8,9,10 & $11 different call series picking up 🤔

1 · Reply

Jellysquid1 Oct. 27 at 2:37 PM

$CRVS Heading Up!

1 · Reply

Jellysquid1 Oct. 26 at 2:54 PM

$CRVS IDIOT BELOW! Med Doctor 👇👇👇👇

2 · Reply

MedicalDoctorInvestor Oct. 25 at 8:09 PM

$CRVS if after market selling is any indicator, Monday morning could be bloody

1 · Reply

TheGunnerAB Oct. 25 at 11:48 AM

$CRVS Short Interest dropped 1.2M shares. That's 120K shares covered per day on average.

1 · Reply

LiquidThetaOptions Oct. 25 at 2:41 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRVS Current Share Price: $7.13 Contracts: $CRVS April 17, 2026 $8 Calls Scale in: $1.86- $2.27 Scale out: $2.89-$3.71 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

MedicalDoctorInvestor Oct. 24 at 8:01 PM

$CRVS I feel the red coming

1 · Reply

KingKai2020 Oct. 24 at 7:04 PM

$CRVS Jan $7.00 calls trade 1000x at $2.25. I assume the same option Buyer as the Dec calls. clearly someone wanting to lever up with measured $ risk.

1 · Reply

tradingjunk321 Oct. 24 at 6:26 PM

$CRVS new! Moore to come

1 · Reply

tradingjunk321 Oct. 24 at 6:04 PM

$CRVS 1000 Jan $7 calls just bought $2, someone saying $9+ by Jan (that's just to break even)!

1 · Reply

lousjamsession Oct. 24 at 5:08 PM

$CRVS dang this should have more watchers flying under the radar.

0 · Reply

tradingjunk321 Oct. 24 at 5:05 PM

$CRVS keep thinking about that new director, there must be some sort of partnership coming with NVO, just a guess! Moore to come!

1 · Reply

Jellysquid1 Oct. 24 at 1:40 PM

$CRVS Recent!

1 · Reply

tradingjunk321 Oct. 24 at 10:54 AM

$CRVS Moore $$$$

0 · Reply

MedicalDoctorInvestor Oct. 23 at 8:31 PM

$CRVS

1 · Reply

Jellysquid1 Oct. 23 at 7:18 PM

$CRVS Good to have a person who worked at Crvs join the institute for follicular Lymphoma ( can only help Out CRVS!)

1 · Reply

MedicalDoctorInvestor Oct. 23 at 1:43 PM

$CRVS it’s going red

1 · Reply

Market Cap	547.68M
Revenue (ttm)	0.00
Net Income (ttm)	-62.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,408,500
Avg Vol	817,970
Day's Range	N/A - N/A
Shares Out	74.51M
Stochastic %K	90%
Beta	0.57
Analysts	Strong Sell
Price Target	$15.00